Trial Profile
A Phase I Single Dose Escalation Study of Two Dosing Schedules of BI 6727 Administered Intravenously in Asian Patients With Various Solid Cancers With Repeated Administration in Patients With Clinical Benefit.
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 29 Jul 2019
Price :
$35
*
At a glance
- Drugs Volasertib (Primary)
- Indications Cancer; Solid tumours
- Focus Adverse reactions
- Sponsors Boehringer Ingelheim Pharmaceuticals
- 20 Oct 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 27 Jul 2011 Planned end date changed from 1 Jul 2011 to 1 Sep 2011 as reported by ClinicalTrials.gov.
- 27 Jul 2011 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.